Ken Griffin Chimerix Inc Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Chimerix Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 33,900 shares of CMRX stock, worth $30,849. This represents 0.0% of its overall portfolio holdings.

Number of Shares

33,900

Previous 48,100 29.52%

Holding current value

$30,849

Previous $42,000 26.19%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.77 - $1.07 $287,634 - $399,699	-373,551 Reduced 25.96%	1,065,478 $990,000
Q2 2024 Aug 14, 2024	SELL	$0.87 - $1.05 $396,857 - $478,965	-456,158 Reduced 24.07%	1,439,029 $1.27 Million
Q1 2024 May 15, 2024	SELL	$0.91 - $1.26 $152,300 - $210,877	-167,363 Reduced 8.11%	1,895,187 $2.01 Million
Q4 2023 Feb 14, 2024	SELL	$0.9 - $1.06 $327,578 - $385,814	-363,976 Reduced 15.0%	2,062,550 $1.98 Million
Q3 2023 Nov 14, 2023	SELL	$0.94 - $1.23 $329,252 - $430,830	-350,269 Reduced 12.61%	2,426,526 $2.33 Million
Q2 2023 Aug 14, 2023	BUY	$1.1 - $1.54 $118,353 - $165,694	107,594 Added 4.03%	2,776,795 $3.36 Million
Q1 2023 May 15, 2023	SELL	$1.19 - $2.09 $165,653 - $290,938	-139,205 Reduced 4.96%	2,669,201 $3.36 Million
Q4 2022 Feb 14, 2023	BUY	$1.67 - $2.35 $123,321 - $173,535	73,845 Added 2.7%	2,808,406 $5.22 Million
Q3 2022 Nov 14, 2022	BUY	$1.81 - $2.76 $4.92 Million - $7.5 Million	2,717,322 Added 15762.64%	2,734,561 $5.28 Million
Q2 2022 Aug 15, 2022	SELL	$1.34 - $5.34 $397,697 - $1.58 Million	-296,789 Reduced 94.51%	17,239 $36,000
Q1 2022 May 16, 2022	BUY	$4.58 - $6.8 $154,455 - $229,323	33,724 Added 12.03%	314,028 $1.44 Million
Q4 2021 Feb 14, 2022	SELL	$5.23 - $7.18 $4.48 Million - $6.15 Million	-855,864 Reduced 75.33%	280,304 $1.8 Million
Q3 2021 Nov 15, 2021	SELL	$5.94 - $8.75 $2.63 Million - $3.88 Million	-443,601 Reduced 28.08%	1,136,168 $7.03 Million
Q2 2021 Aug 16, 2021	BUY	$7.54 - $9.79 $3.89 Million - $5.05 Million	515,828 Added 48.48%	1,579,769 $12.6 Million
Q1 2021 May 17, 2021	BUY	$4.76 - $11.25 $4.95 Million - $11.7 Million	1,039,865 Added 4319.09%	1,063,941 $10.3 Million
Q4 2020 Feb 16, 2021	BUY	$2.43 - $5.42 $32,379 - $72,221	13,325 Added 123.94%	24,076 $116,000
Q3 2020 Nov 16, 2020	SELL	$2.3 - $3.72 $84,444 - $136,579	-36,715 Reduced 77.35%	10,751 $27,000
Q2 2020 Aug 14, 2020	SELL	$1.33 - $3.63 $1.79 Million - $4.89 Million	-1,347,620 Reduced 96.6%	47,466 $147,000
Q1 2020 May 15, 2020	BUY	$1.27 - $2.33 $285,887 - $524,501	225,108 Added 19.24%	1,395,086 $2.01 Million
Q4 2019 Feb 14, 2020	BUY	$1.3 - $2.72 $35,935 - $75,188	27,643 Added 2.42%	1,169,978 $2.38 Million
Q3 2019 Nov 14, 2019	SELL	$1.93 - $4.21 $7,826 - $17,071	-4,055 Reduced 0.35%	1,142,335 $2.68 Million
Q2 2019 Aug 14, 2019	BUY	$2.05 - $4.32 $2.15 Million - $4.52 Million	1,046,575 Added 1048.51%	1,146,390 $4.95 Million
Q1 2019 May 15, 2019	BUY	$1.79 - $3.12 $92,507 - $161,241	51,680 Added 107.36%	99,815 $0
Q4 2018 Feb 14, 2019	SELL	$2.24 - $3.9 $9,555 - $16,637	-4,266 Reduced 8.14%	48,135 $123,000
Q3 2018 Nov 13, 2018	BUY	$3.58 - $4.9 $60,108 - $82,271	16,790 Added 47.15%	52,401 $0
Q2 2018 Aug 10, 2018	SELL	$4.43 - $5.14 $299,357 - $347,335	-67,575 Reduced 65.49%	35,611 $0
Q1 2018 May 11, 2018	BUY	$4.65 - $5.9 $19,762 - $25,075	4,250 Added 4.3%	103,186 $536,000
Q4 2017 Feb 09, 2018	SELL	$4.32 - $5.52 $287,513 - $367,378	-66,554 Reduced 40.22%	98,936 $458,000
Q3 2017 Nov 09, 2017	BUY	$4.35 - $5.25 $719,881 - $868,822	165,490	165,490 $869,000

Others Institutions Holding CMRX

# of Institutions

Shares Held

37M

Call Options Held

52.7K

Put Options Held

130K

View Full List

About CHIMERIX INC

Ticker CMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,622,896
Market Cap $79.7M
Description
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...

More about CMRX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account